Genetic epilepsy with febrile seizures plus (GEFS+)

Genetic epilepsy with febrile seizures plus (GEFS+) is a rare inherited form of epilepsy characterized by the onset of febrile seizures in childhood and the possibility of their evolution into later episodes with various types of seizures, including partial and generalized seizures. This disease is caused by genetic factors and can manifest itself in patients of different ages. About 25% patients have drug-resistant forms of epilepsy. A feature of GEFS+ is the presence of a family history, which suggests the nosology in close relatives. The disease can significantly affect the quality of life of patients and their families, requiring a comprehensive approach to diagnosis and treatment.

History of the disease and interesting historical facts

Genetic epilepsy with febrile seizures plus (GEFS+) was first described in 1997 when researchers found a link between genetic mutations and the phenomenon of febrile seizures. Interest in the disease arose from family studies that demonstrated the continuity of traits among members of the same family. In the following years, mutations in several genes, such as SCN1A, were identified, which became the basis for understanding the pathogenesis of the disease. Research has not only expanded our understanding of epilepsy in general, but also allowed us to better identify GEFS+ as a separate entity. Historical evidence suggests that many famous people, including scientists and artists, suffered from epilepsy, which underlines the importance of researching this condition from both a scientific and ethical point of view.

Epidemiology

According to medical research, GEFS+ occurs with a frequency of approximately 1 in 2000-3000 children. Statistics show that among the total number of patients with epilepsy, GEFS+ is about 1-2%. Surveys show that men and women suffer from this disease equally. It is believed that the disease is more common in children with a family history of epilepsy, and tends to decrease in activity with age. However, in most cases, the need for long-term therapy persists throughout the patient's life, which emphasizes the importance of timely diagnosis and an adequate approach to treatment.

Genetic predisposition to this disease

Genetic predisposition plays a key role in the development of GEFS+. In particular, mutations in the SCN1A, SCN2A and other genes associated with sodium channel function have been identified as fundamental to the development of this condition. Changes in these genes can disrupt neuronal function, causing hyperexcitability and, as a result, seizures. Genetic tests that can identify mutations are becoming increasingly available, making it possible to perform prenatal diagnosis and determine the risk of developing the disease in newborns. It is also necessary to consider multiple factors, such as modifiers and interactions between genes, which can influence the progressive clinical picture of the disease.

Risk factors for the development of this disease

There are a number of risk factors for GEFS+, which include both genetic and exogenous aspects. These include:

• Hereditary predisposition: presence of cases of epilepsy in the family.
• Problems with the development of the nervous system in the perinatal period: hypoxia, infections.
• Head injuries in childhood, which may contribute to seizures.
• Diseases associated with metabolic disorders: hypoglycemia, electrolyte disturbances.
• Stress and sudden changes in lifestyle that can trigger febrile seizures.

These factors, taken together, may increase the likelihood of developing epilepsy. Therefore, understanding these aspects is important for early diagnosis and preventive measures.

Diagnosis of this disease

Diagnosis of GEFS+ requires a comprehensive approach, including:

• Main symptoms: febrile seizures usually occur at temperatures above 38°C and can be generalized or focal.
• Laboratory tests: electrolytes, glucose levels, liver and kidney function tests to rule out metabolic encephalopathy syndrome.
• Radiological examinations: MRI or CT of the brain help to exclude structural changes.
• Other types of diagnostics: EEG (electroencephalogram) to determine specific epileptiform changes.
• Differential diagnosis: it is necessary to exclude other forms of epilepsy, as well as non-epileptic conditions that provoke seizures.

A thorough examination is the basis for establishing the correct diagnosis and determining the treatment strategy.

Treatment

Treatment for GEFS+ traditionally involves several approaches:

• General care: monitoring the patient's condition, providing a safe environment, and talking to the patient and family about the disease.
• Pharmacological treatment: administration of anticonvulsants such as lamotrigine, valproic acid and carbamazepine, depending on the clinical picture.
• Surgical treatment: considered in case of drug-resistant epilepsy in the context of GEFS+.
• Other treatments include physical therapy and psychological support, including cognitive behavioral therapy.

An integrated approach to treatment can significantly improve the quality of life of patients.

List of medications used to treat this disease

The most common anticonvulsant drugs include:

• Lamotrigine
• Valproic acid
• Carbamazepine
• Levetiracetam
• Topiramate

These drugs can be used either in monotherapy or in combination, depending on the clinical situation.

Disease monitoring

Monitoring the health status of patients with GEFS+ includes:

• Control stages: regular examinations by a neurologist, monitoring the effectiveness of therapy and side effects of drugs.
• Prognosis: In most cases, with adequate treatment, patients' condition stabilizes; negative outcomes, such as resistant forms of epilepsy, are less common.
• Complications: both side effects from anticonvulsant therapy and the development of socio-psychological problems such as depression and anxiety disorders are possible.

Regular monitoring allows for timely response to changes in the patient’s condition and adjustment of therapy.

Age-related features of the disease

GEFS+ can occur in different age groups:

• Children: The initial onset of febrile seizures, usually between 6 months and 5 years of age, is often followed by rapid evolution to more severe convulsive episodes.
• Adolescents: the development of more stable forms of epilepsy is possible, the frequency of febrile seizures decreases, but risks of socialization and psychological comfort appear.
• Adults: Clinical presentation may change, medication doses may need to be increased, and new mental health challenges may arise.

Constant monitoring by specialists is necessary at every age to maintain quality of life.

Questions and Answers

• How is hereditary GEFS+? GEFS+ can be inherited, and the risk increases if there are cases in the family.
• Can GEFS+ be prevented? There is no complete prevention, but identifying commercially related diseases can reduce the risk.
• How common are seizures in GEFS+? The frequency of seizures can vary; they may be frequent at the beginning of the disease, but may decrease over time.
• Are there specific triggers for seizures? Stress, sudden changes in body temperature and lack of sleep can be triggers for seizures.
• How long can GEFS+ treatment last? Treatment often continues for the rest of the patient's life, especially if tachyarrhythmias become frequent.

Advice from Dr. Oleg Korzhikov: "When signs of GEFS+ are detected, it is very important to establish the correct diagnosis as early as possible. It is important to remember the importance of interaction with doctors and regular monitoring of health. It is also necessary to take into account the individuality of each case and stay in contact with the attending physician to adjust the therapeutic plan. Epilepsy is not a death sentence, and timely treatment allows you to achieve high results and improve the quality of life."